Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708803 | 0.96 | PKLR (0.32) | PTGS1ALDH1A1CYP3A4MAPK1 | |
| Potassium Ion SCHEMBL3701323 | 0.96 | RAD51 (0.32) | PTGS1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL3697434 | 0.76 | TTR (0.31) | — | |
| SCHEMBL3708804 | 0.74 | TTR (0.31) | — | |
| Lithium Ion SCHEMBL3709427 | 0.64 | HSD11B1 (0.48) | ALDH1A1CYP3A4 | |
| Lithium Ion SCHEMBL31114580 | 0.63 | PKLR (0.42) | PTGS1CYP3A4 | |
| Lithium Ion SCHEMBL5014791 | 0.63 | PKLR (0.42) | PTGS1CYP3A4 | |
| Lithium Ion SCHEMBL3700501 | 0.62 | PTGS1 (0.32) | PTGS1ALDH1A1CYP3A4MAPK1 | |
| Lithium Ion SCHEMBL3699048 | 0.61 | S100A4 (0.46) | ALDH1A1CYP3A4MAPK1 | |
| Lithium Ion SCHEMBL3700335 | 0.61 | CYP3A4 (0.33) | PTGS1ALDH1A1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | PTGS1 1783/4885ALDH1A1 35/4885CYP3A4 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.